Specialists of the domestic pharmaceutical company Farmak have developed and brought to market a drug for the treatment of acute (stroke) and chronic cerebrovascular disorders: Lira (citicoline). The new drug is produced in the form of a solution for injection in 1000 mg ampoules No. 5 and 500 mg ampoules No. 5.
Farmak is actively working in the sphere of treatment of cardiovascular diseases. In particular, much attention is given to ensure comprehensive effective and affordable treatment of acute and chronic cerebrovascular disorders. To achieve this objective, the company's specialists have developed and brought to market the drug product Lira (citicoline).
Lira is indicated in the acute phase of cerebrovascular disorders and for the treatment of cerebrovascular complications and sequelae; in craniocerebral traumas and their consequences, neurological disorders (cognitive, sensitive and motor) caused by degenerative and vascular cerebral disorders.
The course of treatment with the drug is 4-6 weeks.
On February 11, 2021 the Kyiv City Council resolved to sell a land plot to Farmak plant. The resolution was adopted by an absolute majority vote. It concerns the territory where the Kyiv Chemical and Pharmaceutical Plant has been located for 95 years. According to the document, the intended purpose of the land plot is […]
The Press Center’s standpoint for the mass media Farmak plant in Kyiv faces a targeted information attack now. Those who have organized a wave of publications most probably pursue the purpose of manipulating public opinion and deputies of the Kyiv City Council in order to clear a land plot in Podol for yet another construction. […]
In accordance with Decree of the President of Ukraine No. 24/2021 On Granting State Awards on Occasion of the Unity Day of Ukraine Hryhorii Viktorovych Kostiuk, member of the Supervisory Board of Joint Stock Company Farmak, has been awarded the title “Honoured Worker of Pharmacy of Ukraine”. The award has been granted for significant personal [&hellip...